IDH1 and acute myeloid leukemia: Of these, two clinical trials aimed at evaluating single-agent PARPi, talazoparib in cohesin-mutant AML (NCT03974217), and olaparib in IDH1/2 mutant AML are in phase I and II, respectively [22].